These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 32285213)

  • 21. Protein-Bound Uremic Toxins Lowering Effect of Sevelamer in Pre-Dialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized Controlled Trial.
    Takkavatakarn K; Puapatanakul P; Phannajit J; Sukkumme W; Chariyavilaskul P; Sitticharoenchai P; Leelahavanichkul A; Katavetin P; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
    Toxins (Basel); 2021 Sep; 13(10):. PubMed ID: 34678981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
    Floege J; Covic AC; Ketteler M; Mann J; Rastogi A; Spinowitz B; Rakov V; Lisk LJ; Sprague SM
    Nephrol Dial Transplant; 2017 Nov; 32(11):1918-1926. PubMed ID: 28339993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
    Greig SL; Plosker GL
    Drugs; 2015 Apr; 75(5):533-42. PubMed ID: 25761962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
    Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dietary protein-fiber ratio associates with circulating levels of indoxyl sulfate and p-cresyl sulfate in chronic kidney disease patients.
    Rossi M; Johnson DW; Xu H; Carrero JJ; Pascoe E; French C; Campbell KL
    Nutr Metab Cardiovasc Dis; 2015 Sep; 25(9):860-865. PubMed ID: 26026209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
    Sprague SM; Ketteler M
    Expert Opin Drug Saf; 2021 Dec; 20(12):1463-1472. PubMed ID: 34511018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bowel Habits and the Association With Uremic Toxins in Non-Dialysis-Dependent Chronic Kidney Disease Patients.
    Ramos CI; Armani RG; Canziani ME; Ribeiro Dolenga CJ; Nakao LS; Campbell KL; Cuppari L
    J Ren Nutr; 2020 Jan; 30(1):31-35. PubMed ID: 30956092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indoxyl sulfate, not P-cresyl sulfate, is associated with advanced glycation end products in patients on long-term hemodialysis.
    Lin CJ; Lin J; Pan CF; Chuang CK; Liu HL; Sun FJ; Wang TJ; Chen HH; Wu CJ
    Kidney Blood Press Res; 2015; 40(2):121-9. PubMed ID: 25833743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum indoxyl sulfate concentrations associate with progression of chronic kidney disease in children.
    Holle J; Kirchner M; Okun J; Bayazit AK; Obrycki L; Canpolat N; Bulut IK; Azukaitis K; Duzova A; Ranchin B; Shroff R; Candan C; Oh J; Klaus G; Lugani F; Gimpel C; Büscher R; Yilmaz A; Baskin E; Erdogan H; Zaloszyc A; Özcelik G; Drozdz D; Jankauskiene A; Nobili F; Melk A; Querfeld U; Schaefer F;
    PLoS One; 2020; 15(10):e0240446. PubMed ID: 33108385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastrointestinal-related uremic toxins in peritoneal dialysis: a pilot study with a 5-year follow-up.
    Lin CJ; Pan CF; Chuang CK; Liu HL; Sun FJ; Wang TJ; Chen HH; Wu CJ
    Arch Med Res; 2013 Oct; 44(7):535-41. PubMed ID: 24055267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measuring serum total and free indoxyl sulfate and p-cresyl sulfate in chronic kidney disease using UPLC-MS/MS.
    Lin CN; Wu IW; Huang YF; Peng SY; Huang YC; Ning HC
    J Food Drug Anal; 2019 Apr; 27(2):502-509. PubMed ID: 30987721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study.
    Covic AC; Sprague SM; Rastogi A; Ketteler M; Walpen S; Perrin A; Floege J
    Nephron; 2020; 144(9):428-439. PubMed ID: 32585670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Accumulation of Gut Microbiome-derived Indoxyl Sulfate and P-Cresyl Sulfate in Patients With End-stage Renal Disease.
    Lin X; Liang W; Li L; Xiong Q; He S; Zhao J; Guo X; Xiang S; Zhang P; Wang H; Ying C; Yao Y; Zuo X
    J Ren Nutr; 2022 Sep; 32(5):578-586. PubMed ID: 34736844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gut microbiome in hemodialysis patients treated with calcium acetate or treated with sucroferric oxyhydroxide: a pilot study.
    Merino-Ribas A; Araujo R; Bancu I; Graterol F; Vergara A; Noguera-Julian M; Paredes R; Bonal J; Sampaio-Maia B
    Int Urol Nephrol; 2022 Aug; 54(8):2015-2023. PubMed ID: 34923600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients.
    Shima H; Miya K; Okada K; Minakuchi J; Kawashima S
    BMC Res Notes; 2018 Jun; 11(1):363. PubMed ID: 29884226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Liver in Determining Serum Colon-Derived Uremic Solutes.
    Lin CJ; Liou TC; Pan CF; Wu PC; Sun FJ; Liu HL; Chen HH; Wu CJ
    PLoS One; 2015; 10(8):e0134590. PubMed ID: 26258409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating
    Chang JF; Hsieh CY; Liou JC; Lu KC; Zheng CM; Wu MS; Chang SW; Wang TM; Wu CC
    Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Innovative Synbiotic Formulation Decreases Free Serum Indoxyl Sulfate, Small Intestine Permeability and Ameliorates Gastrointestinal Symptoms in a Randomized Pilot Trial in Stage IIIb-IV CKD Patients.
    Cosola C; Rocchetti MT; di Bari I; Acquaviva PM; Maranzano V; Corciulo S; Di Ciaula A; Di Palo DM; La Forgia FM; Fontana S; De Angelis M; Portincasa P; Gesualdo L
    Toxins (Basel); 2021 May; 13(5):. PubMed ID: 34063068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indoxyl sulfate associates with cardiovascular phenotype in children with chronic kidney disease.
    Holle J; Querfeld U; Kirchner M; Anninos A; Okun J; Thurn-Valsassina D; Bayazit A; Niemirska A; Canpolat N; Bulut IK; Duzova A; Anarat A; Shroff R; Bilginer Y; Caliskan S; Candan C; Harambat J; Özcakar ZB; Soylemezoglu O; Tschumi S; Habbig S; Yilmaz E; Balat A; Zurowska A; Cakar N; Kranz B; Ertan P; Melk A; Azukaitis K; Schaefer F
    Pediatr Nephrol; 2019 Dec; 34(12):2571-2582. PubMed ID: 31428929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patients in parallel with loss of residual renal function.
    Viaene L; Meijers BK; Bammens B; Vanrenterghem Y; Evenepoel P
    Perit Dial Int; 2014; 34(1):71-8. PubMed ID: 24179107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.